More about

Adalimumab

News
September 05, 2019
3 min read
Save

Adalimumab well-tolerated by most children with polyarticular JIA

Adalimumab well-tolerated by most children with polyarticular JIA

Adalimumab, with or without methotrexate, is well-tolerated over a period of at least 7 years among most children with polyarticular-course juvenile idiopathic arthritis, according to data published Arthritis Care & Research.

News
August 28, 2019
2 min read
Save

Some patients prescribed biologics also receive topical medications for psoriasis

Some patients prescribed biologics also receive topical medications for psoriasis

In patients with psoriasis, the median time between first and last biologic prescriptions was between 3.3 and 7 months with up to 50% of patients not prescribed a second prescription for the medication, according to researchers in Journal of Drugs in Dermatology.

News
August 16, 2019
7 min read
Save

Arthritis drug market rattles as upadacitinib wins race to FDA approval

Arthritis drug market rattles as upadacitinib wins race to FDA approval

In a landmark FDA approval, AbbVie’s upadacitinib has won the race to enter the drug market as the third JAK inhibitor approved for the treatment of moderate-to-severe rheumatoid arthritis, with the drug expected to be available in the United States within the month.

News
August 06, 2019
4 min read
Save

Joint guidelines explore best practices in NB-UVB therapy for psoriasis

Based on the available literature, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines on ultraviolet light-based therapies for the treatment of psoriasis.

View more